Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.40 |
| ▸ | LPL | P06858 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852340 | 0.90 | ROCK1 (0.43) | ROCK1CA12CA1CA2CA7 | |
| SCHEMBL2782538 | 0.86 | CA1 (0.43) | ROCK1CA12CA1CA2CA7 | |
| SCHEMBL4819962 | 0.85 | HIF1A (0.44) | ROCK1CA12CA1CA2CA7 | |
| SCHEMBL516413 | 0.85 | ROCK1 (0.46) | ROCK1CA12CA1CA2CA7 | |
| SCHEMBL30004376 | 0.85 | ROCK1 (0.46) | ROCK1CA12CA1CA2CA7 | |
| SCHEMBL28960278 | 0.85 | ROCK1 (0.46) | ROCK1CA12CA1CA2CA7 | |
| SCHEMBL3850262 | 0.84 | CYP4F2 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10184702 | 0.84 | TSHR (0.42) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5064664 | 0.83 | UCHL1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22408213 | 0.83 | HIF1A (0.45) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233842-B1 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARB) AGONISTS | KING S COLLEGE LONDON (GB) | 2025-03-26 | — | — | EP | disclosed |
| US-11401265-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON | 2022-08-02 | — | — | US | disclosed |
| US-20210130337-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2021-05-06 | — | — | US | disclosed |
| CN-107207488-B | Bicyclic heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RAR) agonists | 伦敦皇家学院 | 2020-11-17 | — | — | CN | disclosed |
| US-10752616-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON (GB) | 2020-08-25 | — | — | US | disclosed |
| US-20200131165-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2020-04-30 | — | — | US | disclosed |
| US-10385044-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20190010146-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2019-01-10 | — | — | US | disclosed |
| US-9994559-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | KING'S COLLEGE LONDON (GB) | 2018-06-12 | — | — | US | disclosed |
| US-20170327489-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | KING'S COLLEGE LONDON (GB) | 2017-11-16 | — | — | US | disclosed |
| EP-3233842-A1 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RAR ) AGONISTS | King's College London (GB) | 2017-10-25 | — | — | EP | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2016097004-A1 | BICYCLOHETEROARYL-HETEROARYL-BENZOIC ACID COMPOUNDS AS RETINOIC ACID RECEPTOR BETA (RARβ) AGONISTS | KING'S COLLEGE LONDON (GB) | 2016-06-23 | — | — | WO | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130337-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | RARB, RARA, RXRB | ROCK1 921/4885CA12 4409/4885CA1 3634/4885 |
| US-11401265-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | RARB, RARA, RXRB | ROCK1 890/4885CA12 4441/4885CA1 3686/4885 |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | ROCK1 479/4885CA12 2039/4885CA1 2704/4885 |
| US-20200131165-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | RARB, RARA, RXRB | ROCK1 921/4885CA12 4409/4885CA1 3634/4885 |
| US-20190010146-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | RARB, RARA, RXRB | ROCK1 940/4885CA12 4339/4885CA1 3513/4885 |
| US-20170327489-A1 | Bicycloheteroaryl-Heteroaryl-Benzoic Acid Compounds as Retinoic Acid Receptor Beta (RARBeta) Agonists | RARB, RARA, RXRB | ROCK1 921/4885CA12 4409/4885CA1 3634/4885 |
| US-10385044-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | RARB, RARA, RARG | ROCK1 897/4885CA12 4374/4885CA1 3559/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | ROCK1 479/4885CA12 2039/4885CA1 2704/4885 |
| US-10752616-B2 | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RARβ) agonists | RARB, RARA, RXRB | ROCK1 890/4885CA12 4441/4885CA1 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.